Baader Bank Aktiengesellschaft Buys Shares of 4,699 Astrazeneca Plc $AZN

Baader Bank Aktiengesellschaft purchased a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,699 shares of the company’s stock, valued at approximately $920,000.

Other institutional investors have also modified their holdings of the company. Swiss National Bank purchased a new position in Astrazeneca in the first quarter worth $1,202,714,000. SEB Asset Management AB acquired a new position in shares of Astrazeneca during the first quarter worth $1,157,593,000. Bank of New York Mellon Corp lifted its holdings in shares of Astrazeneca by 546.1% during the 1st quarter. Bank of New York Mellon Corp now owns 6,667,812 shares of the company’s stock valued at $1,315,026,000 after purchasing an additional 5,635,812 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Astrazeneca by 552.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after purchasing an additional 4,697,895 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Astrazeneca by 4,529.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 3,783,927 shares of the company’s stock worth $747,099,000 after purchasing an additional 3,702,185 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Stock Performance

Shares of AZN stock opened at $164.14 on Tuesday. The business has a fifty day moving average of $181.80 and a 200 day moving average of $188.30. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market capitalization of $254.56 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, research analysts expect that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.